Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Clover Biopharmaceuticals, Ltd.
  6. News
  7. Summary
    2197   KYG2280A1076

CLOVER BIOPHARMACEUTICALS, LTD.

(2197)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clover Bio's COVID Vaccine Candidate to Begin Phase 2 Clinical Trial as Booster Dose

11/25/2021 | 09:15pm EST


© MT Newswires 2021
All news about CLOVER BIOPHARMACEUTICALS, LTD.
01/06Clover Biopharma Doses First Subjects in Clinical Trial of COVID-19 Vaccine Candidate
MT
01/05Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candid..
GL
01/05Clover Biopharmaceuticals, Ltd. Dosing of First Participants with Homologous Booster Do..
CI
01/04Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-T..
GL
01/04Clover Biopharmaceuticals, Ltd. Announces Construction of New R&D Center in Zhangjiang ..
CI
2021Clover Biopharmaceuticals, Ltd. Announces Executive Changes
CI
2021Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Hum..
AQ
2021Clover Bio, Ascentage Pharma to Collaborate on Potential Combination Therapy for Perito..
MT
2021Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Hum..
AQ
2021Clover Bio Strikes Deal to Supply UNICEF with 414 Million Doses of COVID Vaccine; Share..
MT
More news
Financials
Sales 2021 190 M 29,9 M 29,9 M
Net income 2021 - - -
Net cash 2021 1 616 M 254 M 254 M
P/E ratio 2021 -0,35x
Yield 2021 -
Capitalization 11 610 M 1 828 M 1 829 M
EV / Sales 2021 52,6x
EV / Sales 2022 0,27x
Nbr of Employees -
Free-Float -
Chart CLOVER BIOPHARMACEUTICALS, LTD.
Duration : Period :
Clover Biopharmaceuticals, Ltd. Technical Analysis Chart | 2197 | KYG2280A1076 | MarketScreener
Technical analysis trends CLOVER BIOPHARMACEUTICALS, LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 10,02 CNY
Average target price 16,04 CNY
Spread / Average Target 60,0%
EPS Revisions
Managers and Directors
Joshua Liang Chief Executive Officer & Executive Director
Phillip Eric Lee Chief Financial & Business Development Officer
Peng Liang Chairman
Htay Htay Han Chief Medical Officer-Vaccine Division
Philippe C. Bishop Chief Medical Officer-Oncology
Sector and Competitors
1st jan.Capi. (M$)
CLOVER BIOPHARMACEUTICALS, LTD.-9.43%1 839
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338